News
The day at a glance · 2 min read
Mood · Mixed
+15
Sentiment, −100 to +100
AbbVie Dividend
$1.73
BMY YTD Gain
19.4%+19.4%
Merck Close
$144.71-1.91%
Key driverAbbVie's Qulipta Phase 3 victory opening new intermittent migraine treatment market offset by Biohaven's partial clinical hold on epilepsy candidate opakalim
Daily briefHealthcare· Money365.Market AI ·

AbbVie Migraine Win, Biohaven Regulatory Hold Hit Biotech

Qulipta Phase 3 success expands intermittent migraine market; epilepsy trial setback pressures Biohaven while Bristol Myers gains YTD momentum

Big Pharma & Biotech

Neutral

Amgen Close

$382.47-2.25%
ABBVBMYMRKAMGNLLY
AbbVie (ABBV) reported a Phase 3 victory for Qulipta supporting intermittent treatment for migraine, potentially expanding use without requiring continuous daily dosing and opening a new migraine market segment. The company's board declared a quarterly cash dividend of $1.73 per share.
Bristol Myers Squibb (BMY) has gained 19.4% year to date, driven by growth brands and pipeline progress, though generic pressure on its legacy portfolio continues to warrant caution according to analyst commentary. The stock closed at $63.75, reflecting a -1.02% change from its prior close.
Merck (MRK) closed at $144.71, down -1.91% from the previous trading day in a session where the stock underperformed the broader market.
Amgen (AMGN) settled at $382.47, representing a -2.25% change from its previous close as the stock declined more than the broader market.
Eli Lilly (LLY) was featured in analyst picks as a company on track to double earnings with products ranging from new drugs to other offerings, though specific pipeline details were not disclosed.

FDA & Regulation

Neutral
PFE
Biohaven disclosed that regulators placed a partial hold on a clinical study for its epilepsy drug candidate opakalim, representing a regulatory roadblock that pressured the company's stock while positioning a rival drugmaker to benefit from the setback.
Novavax outlined its transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID and combination vaccine development programs involving Pfizer (PFE).

MedTech & Devices

Neutral

Bioreactor Market 2026

$4.2B

Bioreactor Market 2036

$11.8B+10.9% CAGR
DXCMABT
Dexcom (DXCM), the global leader in glucose biosensing, announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026.
Abbott Laboratories (ABT) was highlighted in research alongside Goldman Sachs and RTX, with growth drivers balanced by costs, supply-chain challenges, and market risks according to analyst commentary.
The global Advanced Bioreactor Systems Market is projected to grow from $4.2 billion in 2026 to $11.8 billion by 2036, at a CAGR of 10.9%, driven by biologics manufacturing, cell and gene therapies, single-use bioreactors, continuous bioprocessing, and AI-based process control.

Health Insurance & Managed Care

Neutral

Elevance 6-Month Return

40%+40%
UNH
Elevance Health has returned more than 40% over the past six months, though the stock is down 6.5% over the past three months while the S&P 500 gained 3.4%, with analysts noting the next leg of growth will come from keeping more of the premium it already collects rather than selling more insurance.
UnitedHealth Group (UNH) was featured in passive income portfolio strategies alongside other holdings, with conservative closed-end fund strategies targeting yields near 7%.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy